Reuters: U.S. Supreme Court to hear arguments for patent case of $4 billion multiple sclerosis drug Copaxone

WASHINGTON — The U.S. Supreme Court on Wednesday heard arguments from Teva Pharmaceutical Industries in defense of the patent protecting its $4 billion multiple sclerosis drug Copaxone, according to a Reuters report. 

 

According to the report, there are two companies developing generic forms of Copaxone, including Sandoz and Mylan. 

 

At issue is a key patent due to expire in September 2015. That patent had been ruled invalid in July 2013 by the U.S. Court of Appeals for the Federal Circuit.

 

According to the report, Mylan plans to launch once the Food and Drug Administration approves its abbreviated new drug application.